Introduction Our aim in this study was to identify the prevalence and clinical characteristics of
LRP4/agrin‐antibody–positive double‐seronegative myasthenia gravis (DNMG). Methods …

Introduction We assessed antibodies against low‐density lipoprotein receptor‐related
protein 4 (LRP4‐Ab) in a Chinese population with myasthenia gravis (MG). Methods Serum …

Myasthenia gravis (MG) is a common disorder that affects the neuromuscular junction. It is
caused by antibodies against acetylcholine receptor and muscle‐specific tyrosine kinase; …

Double-seronegative myasthenia gravis (dSN-MG, without detectable AChR and MuSK
antibodies) presents a serious gap in MG diagnosis and understanding. Recently …

In autoimmune myasthenia gravis (MG), the identification of antibodies and characterization
of serological subgroups is of great importance for diagnosis and management of the …

Objectives To determine whether patients with myasthenia gravis (MG) have serum
antibodies to lipoprotein-related protein 4 (LRP4), a newly identified receptor for agrin that is …

Background and Objective To determine whether human anti-LRP4/agrin antibodies are
pathogenic in mice and to investigate underpinning pathogenic mechanisms. Methods …

Myasthenia gravis (MG) is an autoimmune disorder characterized by a defect in synaptic
transmission at the neuromuscular junction causing fluctuating muscle weakness with a …

Myasthenia gravis (MG) is the most common disorder affecting the neuromuscular junction
(NMJ). MG is frequently caused by autoantibodies against acetylcholine receptor (AChR) …

Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction, where
acetylcholine receptor (AChR), muscle‐specific kinase (MuSK), and low‐density lipoprotein …